Pediatric Retinal Research Laboratory, Eye Research Institute, Oakland University, Rochester, Michigan.
Invest Ophthalmol Vis Sci. 2014 Mar 28;55(3):1884-92. doi: 10.1167/iovs.13-13397.
Inhibition of VEGF is widely used in patients to control neovascularization and decrease vascular permeability. To date, the effect of VEGF inhibition has not been evaluated in the developing retina such as that seen in premature infants. The goal of this study was to address the effect of anti-VEGF treatment on retinal development of a mouse model of retinopathy.
C57BL/6J mice were evaluated using a model of oxygen-induced retinopathy. Test animals were treated at postnatal day (P) 14 with intravitreal injections of the VEGF inhibitor aflibercept (2.5 or 10 μg) in one eye. Control animals were treated with injection of PBS in one eye. The noninjected fellow eyes were used as internal controls. Areas of avascular retina and neovascular tufts in injected (treated) eyes and noninjected fellow eyes were determined at P17, and the difference related to these characteristics was obtained among them. To evaluate the effect of VEGF inhibition on neurogenesis, focal ERG was performed at P21 and P42. Histologic evaluation of the retinal structure was also evaluated at P42.
Aflibercept treatment reduced the amount of neovascular tufts but significantly increased the area of avascular retina (low dose and high dose) at P17. The delayed vascular growth corresponded to decreased ERG amplitudes (at P21 and P42) and structural changes in the retinal layers that persisted (at P42), despite vascular recovery.
Inhibition of VEGF in developing eyes has the short-term effect of delayed vascular growth and the long-term effects of decreased function with persistent changes in the neuroretinal structures.
抑制血管内皮生长因子(VEGF)被广泛用于控制新生血管形成和降低血管通透性。迄今为止,尚未在早产儿等发育中的视网膜中评估 VEGF 抑制的效果。本研究的目的是探讨抗 VEGF 治疗对视网膜病变小鼠模型视网膜发育的影响。
使用氧诱导视网膜病变模型评估 C57BL/6J 小鼠。实验动物于出生后第 14 天(P)通过玻璃体内注射 VEGF 抑制剂阿柏西普(2.5 或 10 μg)治疗一只眼。对照动物的一只眼接受 PBS 注射。未注射的对侧眼作为内部对照。在 P17 时确定注射(治疗)眼和未注射对侧眼的无血管视网膜和新生血管丛的区域,并获得这些特征之间的差异。为了评估 VEGF 抑制对神经发生的影响,在 P21 和 P42 时进行焦点 ERG。还在 P42 时评估视网膜结构的组织学评估。
阿柏西普治疗减少了新生血管丛的数量,但在 P17 时显著增加了无血管视网膜的面积(低剂量和高剂量)。延迟的血管生长与 ERG 幅度降低(在 P21 和 P42)以及持续存在的视网膜层结构变化(在 P42)相对应,尽管血管恢复。
在发育中的眼睛中抑制 VEGF 具有短期延迟血管生长的作用,以及长期功能下降和神经视网膜结构持续变化的作用。